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Abstract
Longitudinal and survival data are frequently collected in biomedical studies. The research
questions of interest in these studies often require separate analysis of the outcomes. But
in many occasions interest also lies in studying their association structures, such as in
biomarker research, where the clinical studies are designed to identify biomarkers with
strong prognostic capabilities for event time outcomes. In the separate analyses, a linear
mixed-effects model is used for modeling the longitudinal data to study the changing trend
of the response overtime when controlling some covariates and a survival model is used to
model the time-to-event data. A common issue in longitudinal studies is that informative
dropout in the data can cause bias in the analysis. Associations between longitudinal
and survival data can occur in the explanatory variables or through stochastic dependence
between the subject-specific random effect component of the longitudinal model and the
survival model. Ignoring the association between the longitudinal and survival data can
result in biased inference. The joint model can account for these issues and simultaneously
analyze the longitudinal and time-to-event data. This approach enables researchers to
obtain more accurate inference regarding the survival probability to certain event when
the longitudinal responses associated with the survival response or outcome-dependent
study dropout.
In an HIV/AIDS study, our primary interest is to compare the survival for the patients
with two antiretroviral drugs, Didanosine (ddl) and Zalcitabine (ddC) with some other
risk factors. We also want to determine how the biomarker-CD4 lymphocyte cell counts
changed over the period of the study. We use separate analysis and the joint model to
analyze the survival and longitudinal outcome and then compare the two analysis results.
In the longitudinal analysis, we used a linear mixed-effects model to fit the CD4 cell counts
using a random intercept and slope for the observation time. In the survival analysis, we
compared the survival between the two treatment groups by using a cox-proportional
hazard model. Then a joint model was fitted by using the fitted longitudinal and survival
objects. To compare the separate analysis and the joint analysis, we use the Akaike’s
Information Criteria (AIC). The joint model was shown to be better than the separate
analyses of the longitudinal models and survival models with a smaller AIC value. Using
the joint model for inference on the HIV study, Zalcitabine (ddC) was significantly effective
in reducing a person’s risk of death. The risk of death was 1.44 times as likely for patients
assigned to ddl as compared to the patients assigned to ddC. The previous diagnosis result
and observation time were significant predictors of the change in CD4 cell count at a 0.05
significance level. A patient having a previous diagnosis of AIDS at the study entry led
to a decrease in CD4 cell counts thus, a patient was more likely to die or the disease
progressed. The joint model showed a significant association between the CD4 count and
survival: with higher CD4 count, the survival probability is also significantly higher (or
the hazard of death is lower). The joint model approach provided more accurate inference
than the separate approaches for the HIV study.

Keywords: longitudinal data, time-to-event data, linear mixed-effects model, sur
vival model, cox-proportional hazard model, joint modelling, HIV/AIDS study
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1

In tro d u ctio n

Efforts to control the HIV/AIDS disease have increased significantly in recent years,
but the virus continues to spread at an alarming rate. Clinical trials have been con
ducted to alter and enhance the standard HIV/AIDS treatment regimen. Researchers
who conduct clinical trials often collect longitudinal and survival data. The goal of
researchers who conduct longitudinal clinical trials on HIV/AIDS is to understand
how the disease progresses over time and to identify risk factors for the disease. For
example, in a study involving patients with HIV symptoms, researchers performed
repeated measurements of patients’ CD4 lymphocyte cell counts to understand the
progression of disease with time and how risk factors such as gender, previous op
portunistic infection, and Zidovudine (AZT) impact a person’s chances of disease
progression [1]. In the same study, researchers used survival data, also known as
time-to-event data, to study treatment effects of HIV/AIDS medications over a span
of time until an event of interest occurred.
Longitudinal and time-to-event data are frequently used in biomedical studies.
Researchers may also use longitudinal and time to event data when studying the
effect of endogenous time-dependent covariates measured repeatedly over time and
when attempting to correct for nonrandom dropout. To analyze longitudinal and
time-to-event data in HIV/AIDS studies, researchers use joint and separate models.
A survival model combined with a model that enables researchers to study the effects
of endogenous time-dependent covariates measured repeatedly and over time is an
example of a joint model [7]. Alternatively, researchers conduct separate analyses in
studies that include longitudinal and time-to-event data. A popular separate analysis
is to analyzing longitudinal using a linear mixed-effects model and analyze time-toevent data using a survival model. A linear mixed-effects model is used to describe

the process of the repeated measurements over time and study for the treatment effect
and the survival model is to analyze the treatment effect on survival up until an event
of interest occurs [7]. The separate model approach does not enable researchers to
establish if there is an association between the components of the two models.
The joint model approach is complex but enables researchers to establish if an
association exists.

Another advantage of using the joint model approach is that

it enables researchers to conduct survival and longitudinal analyses simultaneously.
Due to the complexity of the joint modeling approach, it is under-used in clinical
research. The objective of this thesis is to provide insight and understanding into
the joint modeling process. We will first discuss longitudinal studies and introduce
linear mixed-effects models to analyze the longitudinal data. Next, we will introduce
the survival model to analyze time-to-event data with nonparametric methods and
the cox proportional hazard model. Furthermore, we will construct a joint model for
longitudinal with time-to-event data. We will focus on a randomized clinical trial
involving patients with HIV/AIDS to provide detailed analytic methods for joint
modeling using the statistical software R [17].
In our study of interest, researchers collected longitudinal and survival data and
compared the efficacy and safety of two antiretroviral drugs. The two antiretroviral
drugs were used to treat patients who were intolerant to zidovudine (AZT) therapy [1].
A total of 467 patients with HIV or low CD4 counts were enrolled into the study. The
467 patients were each randomly assigned to one of two groups. One group of patients
received an antiretroviral drug called Didanosine (ddl). The other group of patients
received an antiretroviral drug called Zalcitabine (ddC). Researchers compared the
effects of the two treatments and studied how the patients’ CD4 cell counts changed
over the course of the study. Our goal is to fit a joint model and conduct diagnostic
analysis to ensure that the researchers of this study made valid inferences regarding
9

the effects of ddl and ddC on the survival of HIV/AIDS patients.

1.1

C linical Trial

We will first provide background into biomedical research and the statistical methods
used to analyze data. A clinical trial is conducted by researchers who want to study
subjects impacted by or exposed to a disease or risk factor. Researchers use clinical
trials to compare new intervention methods to existing treatment methods. Clinical
trials are used to enhance medical intervention options for a disease or outcome,
thus finding better ways to prevent, screen, diagnose, or treat a disease. To carry
out a clinical trial, subjects are randomly assigned to different intervention groups or
stratified according to different prognostic factors such as age or gender. Many clinical
trials involve following up with patients for a long period of time. The follow-up time
for the study may range from a few weeks to many years.
Different statistical procedures are used clinical trial studies. These procedures are
useful in clinical research and provide vital information about intervention methods.
For example, in the case of an oncology clinical trial, an intervention method is
investigated to test the response on tumor shrinkage. In HIV/AIDS studies, different
treatments are used to examine the change of CD4 cells on the survival time of patients
with HIV. Typically, longitudinal data in HIV/AIDS studies consists of recording
measurements of CD4 cell counts taken at various points in time throughout the
study period. CD4 cell counts are considered important biomarkers of HIV disease
progression because CD4 cell counts are an important part of the immune system,
which begin to deplete as the virus infects the body.
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1.2

L ongitudinal D a ta A nalysis

A longitudinal study is a type of randomized controlled experiment in which data is
collected on repeated measurements for the same subject at a series of time points.
In practice, the measurements are observed at discrete time points, usually including
baseline measurements. In medical research, the focus is often on interrelationships
between the variables of repeated measurements on a continuous response. A familiar
example is that of HIV clinical trials, where covariates, including treatment assign
ment, demographic information, and measurements on immunologic and virologic
status such as CD4 cell counts are recorded at baseline and then taken at subsequent
clinic visits. Although it is common to assume independence between subjects, such
repeated measurements are correlated within-subjects and therefore require special
statistical methods for validity and inference. The researcher can establish sequences
of events because longitudinal studies extend beyond a single moment in time.

1.2.1

Linear M ixed-Effects M odels

We will use linear mixed-effects models to analyze the longitudinal data. The linear
mixed-effects (LME) model is a type of model that uses fixed effects and random
effects in the same analyses. A fixed effect contains covariates that relate to the ith
patient at time of their j th measurement, where i = 1, ...m and j = 1,...., rq. The
primary interest in the model are the fixed effects, which include levels that could be
used multiple times for repeated measurements. A random effect is a patient-specific
coefficient that represents between-patients heterogeneity in an outcome variable that
cannot be explained by measured covariates [4]. The LME model is widely used in
statistical analyses of longitudinal data as it considers both the within-subjects and
between-subjects variation. The LME model allows for a wide variety of correlation
patterns. The LME model is also effective in modeling data that is missing at random.
11

Most models exclude data on a subject if one measurement is missing. In cases where
data on a subject is missing at random, the LME model includes the available data on
that subject instead of excluding data on the subject all together. The LME model is
also preferred when there is uneven spacing of repeated measurements. For example,
in our application study, measurements of CD4 cell counts for HIV/AIDS patients
were recorded at 0, 2, 6, 12, and 18 months.
A common model-based approach for longitudinal measurements assumes inde
pendence between subjects z, where each measurement is a realization of a Gaussian
random variable [21]. The LME model can be used as an extension of the general
regression model in equation (1). In equation (1), Y is a N x 1 response vector and
we denote yij as the jth measurement on the zth subject. X is a N x (p + 1) matrix,
where p are the number of explanatory variables. ¡3 is a (p+ 1) x 1 dimensional vector
of fixed-effects regression coefficients, and e is a N x 1 vector of the measurement
errors, e ~ V (0,of). To extend the general regression model (1) to the LME model,
we need to consider a random effect. In the equation we use Z to denote an N x q
design matrix for the ^-dimension random effects 7; in which Z could be a submatrix
of the X matrix. 7 is a q x 1 vector of the random effects. We assume 7 ~ N ( 0, D)
and 7,£ are independent. We denote E* as the variance-covariance matrix of the
response z/j with var{Y{) = E* = Z i D Z j + cr^Ini.
Y = X /3 + e

( 1)

By inclusion of the random effects component, equation (1) is extended to the
linear mixed-effects model in equation (2):

Y = XQ

+ Z7 + e
12

( 2)

Different models for longitudinal data differ on the correlation structure for error
term [21]. We will use the LME form given by equation (3) where Y¿j is the response
variable measured on subject i = 1

m at time point ¿¿j, with j =

m is

the number of subjects and rq is the number of measurements for subject i. Wu(tij)
is the unobserved random process; where we change notation from Z in equation (2)
to

Sij are independent realizations of zero-mean Gaussian random variables

with variance cr2 representing pure measurement error, Hi(Uj) is the mean response for
subjects i at time point ti3, which represents the fixed effects and can have linear form
such as xfj/3. From this point on we will assume that

represents pure measurement

error.
hq —fii(tij) -I- W

\ T E-ij

(d)

In this paper we will distinguish between the models of longitudinal process and of
the survival process to construct the joint modelling of the two processes. We want
to distinguish between the random effects component Wi(tij) in each process. The
random effects component is subscript with a T ’, Wu(tij), to denote that it belongs
to the longitudinal process of the two-stage joint modelling process. In the survival
process, the random effects component of the survival model will be subscripted with
a ‘2’. We will provide more details on the relationship of these components later in
the paper.
Furthermore, some authors choose to decompose the unobserved random process
Wi(Uj) into two components in an additive way. For example, model (4) uses Diggle’s,
and Laird and Ware’s proposed linear mixed-effects model [4] [9]. In this model U¿ are
m independent realizations of a r-dimension multivariate Gaussian random variable
and di are r-dimensional vectors of explanatory variables for the random process Z7¿.
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The Vi(tij) are m, independent realizations of a stationary Gaussian process.

Wi(tij) = d ' i(Ui) + Vi{tij)

(4)

Guo and Carlin also use Diggle’s and Laird Ware’s subject-specific (LME) model
in an application to an HIV study. For our study of interest, we use the form of
longitudinal model proposed in their paper [7] and use error structure proposed by
Laird and Diggle in their paper [9]. We start with notation to the longitudinal model
in which every parameter will have a subscript‘T for the combined methods later. The
sequence of measurements yn,

•••, Him f°r the ith subjects at times tu, ti2, ...,tin.

is modeled in the LME model (3), where yßUj) = x^(t)/?i is the mean response,
W\i(t) = d J ^ U i incorporates subject-specihc random effects and Eij ~ N(0,a^) is
a sequence of mutually independent pure measurement errors account for variability
between subjects.

In application to the HIV study, Wu(t) is the true individual

level CD4 trajectories after adjusting for the overall mean trajectory and the fixed
effects. The vectors Xu(t) and ß\ represent time-varying explanatory variables and
their coefficients for the longitudinal process, respectively.

The U{ are vectors of

random effects corresponding to the explanatory variables du(t). We will discuss a
linear mixed-effects model with random intercept only and then a model with the
combination of random intercept and random slope in our application to the HIV
study.

1.3

T im e-to-E ven t D a ta A nalysis

In survival analysis, subjects are followed over a specified length of time in order to
study the relationship of survival up to a certain event point with some risk factors.
Time-to-event data may be based on events other than death, such as recurrence
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of a disease, disease progression, or discharge from the hospital. For example, in
biomedical studies we study treatment effects of HIV/AIDS medications over a span
of time until death or disease progression. Survival data includes a censoring variable
which indicates if an event occurred or did not occur during the observation time.
Observations are called censored when the information about their survival time is
incomplete; the most commonly encountered form is right censoring. Right censoring
is indicated when a patient does not experience the event of interest for the duration
of the study. The survival time for this person is considered to be at least as long
as the duration of the study. Right censoring could also occur when a person drops
out of the study before the end of the study observation time and did not experience
the event. This person’s survival time is said to be censored, since we know that the
event of interest did not happen while this person was under observation. Censoring
is an important issue in survival analysis, representing a particular type of missing
data. Survival analysis requires censoring be random and non-informative to avoid
bias. This means that the time-to-event and censored are independent.
In survival analysis, researchers can use life tables, Kaplan-Meier curves to de
scribe the survival times of patients of some intervention groups. We use log-rank
tests to compare the survival curves of two or more groups. To describe the effect
of some explanatory variables on survival time, we can use cox proportional hazards
regression or parametric survival models. We will provide a brief description of the
study methods using the data from the HIV study.

1.3.1

N onparam etric M ethods

The survival and hazard functions are key concepts in survival analysis for describing
the distribution of event times. The main characteristics in survival functions are the
response variable y as the surviving time until the occurrence of a well-defined event,
15

which could be censored, in the sense that for some units the event of interest has not
occurred at the time the data are collected. First, we let T be a non-negative random
variable representing the waiting time until the occurrence of an event; usually the
time of failure. We let f{t) be the density function of T.

The survival function

S(t) is the probability of time-to-event, denoted by the random variable T, beyond
some time point t. For example, we examine the probability of death or disease
progression up to 18 months for different treatment groups to test the efficacy of the
intervention method on patients with HIV. The survival function is defined on the
domain t G [0,oo) and has a probability range from [0,1]. We assume at t = 0, the
probability of survival will be one (-5(0) = 1) unless there is an immediate death, and
S(t) will approach zero as age increases without bound, indicating that life eventually
ends.
The hazard function A(£), is defined as the instantaneous rate of death occurring
at time t, given that failure time did not occur up to that time or before that time.
We denote the survival function and hazard function respectively:

S(t) = P ( T > t)

X(t)

lim
A ->0+

P(t < T < t + A t|T > t)
At

(5)

(6 )

We also denote the hazard function as a relation between the density function and
survival function or the first derivative of the survival function and the survival func
tion:
A(i)

m

m

S(t)

(7)

Generally in survival studies, we wish to describe the relationship of a factor of
interest (e.g. treatment) to the response, in the presence of several covariates, such
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as age, gender, race, etc.

In HIV studies, we analyze how the treatment affects

survival. Methods to analyze the relationship of a set of predictor variables with
the survival time include parametric, nonparametric and semiparametric approaches.
This paper will consider nonparametric methods such as the Kaplan-Meier method
and the semiparametric cox-proportional hazard model because they does not assume
a specific distribution.
The logrank test and Kaplan-Meier method are widely used to compare and es
timate survival probabilities as a function of time, respectively. The Kaplan-Meier
method can be used to obtain univariate descriptive statistics for survival data, in
cluding the median survival time, and compare the survival probability for two or
more groups of subjects. Graphically, Kaplan-Meier curves are useful in obtaining
the probability of survival at different time points where life tables show us the num
ber of patients at risk and survival probability for each observed time point in a
table.
A life table is useful in survival analysis because it summarizes survival data
in terms of the number of events and the proportion surviving at each event time
point. For example, researchers could construct life tables to compare the amount
of patients alive at various time points in each treatment group. The life table will
provide information on the intervention method in cases of comparing the efficacy
of two treatments or cases where the treatment is not working and the study needs
to stop. For notation in our application we will denote a few variables. Let ¿(i) <
2) < ... < i(fc) be the ordered subset of k < n unique observed failure times from
the observed survival times. Let di be the number of failures which occurs at ti and
rii be the number of patients at risk before time ti. We also denote the risk set
R(ti) and the relation di/rii as the probability of failure at time £* [21]. Based on the
survival function previously mentioned we estimate the product-limiting estimate of
17

the survival function and hazard function respectively:

if t < t(i)
S(t)

(8 )
)

if

t >t(1)

(9)

A(t)

The variance of the product-limit estimate of the survival function can be obtained
by
( 10)
Following the Kaplan-Meier method, researchers would then like to analyze the
effect of predictor variables on the survival time. Kaplan-Meier curves do not work
easily with quantitative predictors such as gene expression, CD4 count, or age. Coxproportional hazard regression is usually used when the data contains quantitative
predictor variables. It allows testing for differences in survival times of two or more
groups of interest, while allowing to adjust for covariates of interest. The Cox propor
tional hazard model extends the logrank test by allowing the inclusion of additional
covariates. The cox regression model use the hazard format instead of the survival
probability, which makes it easy to interpret information regarding the relationship
of the hazard function to predictors.

1.3.2

C ox-Proportional Hazard M odel

The Cox-proportional hazard model is used when the study interest is to get inference
for the model parameters of a time-to-event process. In the Cox-proportional hazard
model, the hazard of an individual with some covariates is proportional to a baseline
function of time, where the baseline hazard function has no specified form. This
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model allows for fixed covariates that do not change over time and parameters are
estimated by maximizing the partial likelihood. The covariates can also include timedependent variables. Their corresponding hazard function are given in equations (11)
and (12) respectively, where A0(t) is the unspecified baseline hazard function.

Ai(t\X) = A0(t)exp{Xi(3}

( ii)

A¿(t X) = A0(t)exp{Xi(t)P}

(12)

We use the notations from Guo and Carlin’s [7] in the cox proportional hazard
model in equation (13), where the vectors x j( t) and fa are possibly time-dependent
explanatory variables and their corresponding regression coefficients. W 2 i(t) includes
subject-specific covariate effects and an intercept. Here, the random effects compo
nent W 2 i(t) in the survival model is subscripted with a ‘2’ to denote that it belongs to
the survival process. This is to distinguish between the random effects components
in the construction of the two-stage joint modelling process in the next section.

Ai(t) = X0(t)exp{xJ(t)fa + W2i(t)}

2
2.1

(13)

Join t M o d ellin g
L iterature R eview

It has become increasingly common in survival studies to record the values of key
longitudinal covariates until the occurrence of survival time of a subject. This leads
to informative dropout of the longitudinal data, which also complicates the survival
analysis. Furthermore, in a survival analysis setting where the covariate of interest
is time-dependent, either the entire history of the covariate measurement of every
19

subject, or, measurements of the covariate at each time of death occurrence or dis
ease progression for all subjects in the risk set is needed. By modelling the covariates
over time, we enhance the survival analysis since we can interpolate covariate values
between the observed measurements to the specific times of death or disease progres
sion, with use of the entire history of the subjects. Modelling the covariate also allows
adjustment for covariate measurement error, which is known to result in biased esti
mates of relative risk parameters [6]. In addition, we can obtain improved covariate
tracking estimates by adjusting for informative right censoring of the repeated mea
surements by the disease progression. Therefore to account for the association in the
separate models researchers use joint modelling to handle irregularity and measure
time-varying covariates correctly [2]. We defined a joint model in this paper as a
survival model combined with a longitudinal model that enables researchers to study
the effects of endogenous time dependent covariates measured repeatedly and over
time.
Typically, a linear mixed-effects model is used first to describe the process of the
repeated measurements over time and study for the treatment effect. A common
problem in longitudinal studies is that informative dropout in the data could cause
bias in the analysis. To account for informative dropout, a number of model-based
approaches have been proposed to jointly model longitudinal outcome and the dropout
mechanism (Wu and Carroll, DeGruttola and Tu, Little, Hogan and Laird [11]). We
will use a linear mixed-effects model to analyze the repeated measurement of timedependent variables over time due to its popularity and simplicity.
After the linear mixed-effects, researchers use survival models to analyze the treat
ment effect up until an event of interest occurs [7]. A widely used survival model is
the proportional hazard model. Various approaches have been proposed under this
framework including the regression method from Pawitan and Self, Tsiatis, DeGrut20

tola and Wulfsohn, the likelihood-based approaches from DeGruttola and Tu, Faucett
and Thomas, Wulfsohn and Tsiatis [23], Henderson, Diggle and Dobson, and Song,
Davidian and Tsiatis), corrected score (Wang) and conditional score (Tsiatis and Davidian, Song, Davidian and Tsiatis) approaches [20]. In HIV/AIDS studies it is known
that the effect of antiretroviral treatments may decay after some time, therefore the
traditional hazard assumption may be too restrictive in this case. An áppealing alter
native is the time-varying coefficient proportional hazards model proposed by Song
and Wang [20], which allows the effect of the coefficients to vary over time.
Although there are many different approaches to construct models for the lon
gitudinal and the time to event data, the separate model approach does not enable
researchers to establish if there is an association between the components of the two
models. Associations between longitudinal and survival data can occur in the ex
planatory variables or through stochastic dependence between the subject-specific
random effects component of the longitudinal model and the survival model. We also
assume associations between the drop-out process; when a missing longitudinal mea
surement terminates the sequence of longitudinal measurements, and the censoring
process. When association between the two processes exists, we use a joint model to
obtain less biased and more efficient inferences. The joint model approach is complex
but enables researchers to establish if an association exists.
Model-based approaches for each type of analysis have been extensively described
in the literature in HIV/AIDS studies. Clayton proposed a comprehensive model that
combined the covariate tracking and disease risk models to estimate parameters of
similar models. DeGruttola and Tu [3] and Tsiatis et al. [22] consider the progression
of CD4 lymphocyte counts and survival time in patients of AIDS. DeGruttola and
Tu assume that the joint distribution of log CD4 counts and some transformation of
survival time are multivariate normally distributed. This formulation allows them to
21

use the modified EM algorithm from Laire and Ware [14] to fit the model. Using a
Cox-proportional hazard model, Tsiatis et al. model the hazard of death as a function
of the conditional expectation of the ‘true’ log CD4 counts given the history of the
observed counts. They proposed a two-step procedure for fitting their model. First
they assume a growth curve random components model with normal error for the
true CD4 count and used a modified EM algorithm. Then they substituted these
estimates into the proportional hazard model and used the cox regression to obtain
estimates of the survival parameters.
Self and Pawitan proposed a similar two-step procedure for parameter estimation
where they condition on the survival information when computing expected values
of the covariates. They, like many others, used partial likelihood methods to obtain
estimates of the disease risk parameters and maximum likelihood methods to model
jointly immunologic markers, time to infection, and time to AIDS [12]. Wulfsohn
and Tsiatis suggest that the joint maximum likelihood method is among the most
satisfactory approaches to combine information. The approach described by Wulf
sohn and Tsiatis is semiparametric in that no parametric assumptions are imposed
on the baseline hazard function in the Cox model, while the random effects in the
longitudinal component are assumed to be normally distributed. An attractive fea
ture of this approach is its robustness against departure from the normal random
effects assumption. It is said to be as efficient as a semiparametric random effects
model proposed by Song, Davidian, and Tsiatis. Many also consider fully parametric
Weibull regression models for the times to disease and infection. On the other hand,
Faucett and Thomas used simulation studies to compare the analysis of the joint co
variate tracking and disease risk model using Gibbs sampling to separate the analysis
of each component.
To illustrate the association between the longitudinal component and survival
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component, Henderson et al.

proposed a LME model for the ith subject via an

unobserved or latent zero Gaussian process W(t) = {Wu(t), W2i(t)}, which is realized
independently in different subjects. They assumed that the latent process forces a
pair of linked longitudinal and survival sub-models. The longitudinal component has
the following format:
Yij = Hi(Uj) + Wu(Uj) + Eij
Where

(14)

is the mean response which could be described by a linear model Xi(t)fa

Eij ~ iV(0, <
j ^) is a sequence of mutually independent measurement errors. They as
sumed

could be describe by a linear model where Ui(t) = Xu(t)Tfa. The survival

component has the form as in equation (15), where fait) is the hazard function and
A0(t) is the baseline hazard function. x 2i(t) and fa represent time-varying explana
tory variables and their coefficients for the survival process, respectively. W2l(t) is an
unobserved random process for the survival process.

Ai(t) = A0(t) exp(x2i(t)Tfa + W2i(t))

2.2

(15)

Form ulation o f th e Joint M odel

We will use the longitudinal model (14) and survival model (15) in the formulation of
the joint model. The association between the longitudinal and survival components
can arise in two ways. One is through common explanatory variables and the other
is through stochastic dependence between the longitudinal and survival process. The
association is thus between Wu and W2{ in equation (14) and (15) as proposed by
Henderson et al. They propose to jointly model the two processes via a latent zeromean bivariate Gaussian process on ( W u , W 2i)T, which is independent for different
subjects. W\i{t) and W2i(t) link the longitudinal model in the LME from equation (14)
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with the cox-proportional hazard model (15) together. The joint model is composed
by the two linked sub-models, which they refer to as the longitudinal measurement
model and the intensity survival model. When association between the two processes
exists, the joint model provides less biased and more efficient inferences than the
separate analysis.

3
3.1

A p p lica tio n to H IV S tu d y
C linical background

The availability of an increasing number of antiretroviral agents and the rapid evolu
tion of new information has led to new treatment regimens for patients infected with
HIV. A current treatment regimen used to treat patients with HIV/AIDS is Zidovu
dine (AZT) therapy. Anti-HIV drugs such as AZT slows down or prevents damage
to the immune system. These drugs also reduces the risk of developing AIDS-related
illnesses. It is known however, that patients can be intolerant to AZT or experience
a ‘failure’. In such cases, researchers provide alternative intervention methods or
treatment such as the antiretroviral drugs: Didanosine (ddl) and Zalcitabine (ddC).
Both drugs are commonly used to treat patients with HIV who cannot tolerate AZT
or who had disease progression despite it [1]. It is also common in HIV studies to
collect repeated measurements of important biomarkers of HIV progression such as
CD4 lymphocyte cell count in a sample of blood and viral loads [15]. CD4 cell are
an important part of the immune system, which begin to deplete as the virus infects
the body. We note that a decrease in CD4 cell counts indicates the degree of im
munosuppression. Our objective is to investigate the change of CD4 cell count over
the period of the study to determine if the two drugs impact the survival of patients
using the HIV dataset.
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3.2

D escription o f D ataset

The HIV study was a randomized clinical trial in which both longitudinal and survival
data were collected to compare the efficacy and safety of two antiretroviral drugs in
treating patients who had failed or were intolerant of Zidovudine (AZT) therapy [1].
The study enrolled 467 patients from December 1990 through September 1991. The
patients were enrolled if they met the following criterion: they had an AIDS-defining
condition or they had two CD4 counts of 300 cells or less per cubic millimeter, with
either a positive serologic test for HIV or a clinician’s working diagnosis of HIV
infection; and they had undergone AZT therapy that led to intolerance of the drug or
progression of disease during therapy [1]. The patients were then randomized to receive
two antiretroviral drugs, either Didanosine (ddl) or Zalcitabine (ddC). However, a
patient was allowed to switch drug treatment after 3 months with a washout period of
at least 3 days. The patient data was then censored at the time of drug re-assignment.
The dataset consisted of 1408 observations on 9 variables. The data consisted of
three continuous explanatory variables: the square root of the CD4 lymphocyte cell
count, but for simplicity reasons we will refer to as CD4, Time (the time to death or
censoring), and Obstime (the observed time points for CD4 measurements). CD4 cell
counts were recorded at baseline (0 months) and at various time points (2, 6, 12 and
18 months) during the trial. The data also included six binary explanatory variables:
Drug (ddC, ddl), Death (censoring=0, d eath = l), Gender (male, female), PrevOI
(previous opportunistic infection of AIDS diagnosis or no previous AIDS diagnosis
at study entry), and AZT (failure or intolerance). In total, 230 patients received ddl
and 237 received ddC. There were 45 females and 422 males involved in the study.
A total of 160 patients did not have a previous diagnosis of AIDS while 307 patients
did have a diagnosis of AIDS at beginning of the study. There were 292 patients who
were intolerant to AZT and 175 experienced a ‘failure’ to AZT, meaning the disease
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progressed despite AZT.
Let Dij denote the square root of the jth CD4 count measurement on the ith.
patient in the trial, j — 1 ,..., n*, i — 1 ,. . . , m. Four explanatory variables as main
effects were included in the analysis: Drug(ddl, ddC), Gender(male, female), PrevOI(AIDS,noAIDS), and AZT(intolerance, failure). The main goal of the study is to
analyze the association of among CD4 count and survival, druggroup, gender, AIDSdiagnosis at baseline and AZT intolerance, accounting for all relevant correlations
and subject-specific random effects.

3.2.1

E xploratory D ata A nalysis

To visualize the dataset, we used exploratory plots of the CD4 cell counts at each
observed time point in Figure 1 and the CD4 counts at each observed time separated
by treatment in Figure 2. The figures allow us to study how the CD4 cell count
changes over time and determine the shape of the distributions.

Figure 1 shows

that the median of the CD4 counts was greater for the beginning months of the
trial. We observed that the CD4 cell counts decreased at each observed month for
all patients. The median CD4 count at each time point was between 5 and 10. The
summary statistics value the median of the CD4 cell count at 6.083. However, we see
outliers at months 2, 6, and 18 months. The boxplot for month 12 presents the most
variability represented by the IQR. The shape of each distribution is right skewed
and contains outliers. The dataset used a square root transformation of CD4 cell
count however still see some skewness. The boxplots show high outliers after the
baseline measurements, meaning there were patients with exceptionally high CD4
cell counts. Furthermore, we wanted to investigate how the CD4 cell count changes
for each treatment group at each time point to detect a pattern. In Figure 2, the
patients who received ddC had a lower median CD4 cell count than the patients who
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received ddl during months 0-12. However, at month 18, the median CD4 cell count
was higher in the ddC group compared to the ddl. It appears that at the end of the
study patients assigned to ddC had a better chance of surviving or the disease has
not progressed. However, there does not appear to be a big difference between the
two treatment groups.
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Figure 1: Boxplot illustrating the CD4 cell counts recorded at time points: 0, 2, 6,
12, and 18 months for all subjects
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Figure 2: Side-by-side boxplots illustrating the CD4 cell counts recorded at time
points: 0, 2, 6, 12, and 18 months for both treatment groups

3.3

L ongitudinal D ata A nalysis

3.3.1

Linear M ixed-Effects M odel

We first examine the change of CD4 cell count throughout the time of the study and
compare the two drugs when controlling other covariates. To analyze the repeated

CD4 cell measures we use linear mixed-effects models.
The linear mixed-effects models can be modeled as:

Uij — fill + Pl2 (Uj) + Wi i + Eij,

(16)

where ylJ is the response of the j th CD4 cell count measured on ith patient in jth
measurement, j — l,...,n* and i = l,...n where n — 467 subjects followed over the
period of the study [0-18 months]. /3n is the intercept and /3i 2 is the observation
time parameter and Wu is the intercept random effect. The fitted model shows a
significant negative effect of observation time on CD4 count. But this model only
assumes subjects have different CD4 count at the baseline, their decreasing rate are
all the same with time. We know that the AIC value for the model will be higher
than the models we fit next. Therefore, we do not include the output table in the
paper.
Next, in equation (17), we fit a linear mixed-effects model with random intercept
and slope for Obstime. This model also assumes the change rate of CD4 with time are
different with different subject besides assuming different baseline CD4 counts. From
equation (16) we include the random effects for intercept and slope over time, W\i(Uj).
We denote Wu(Uj) = Uu + U2 i(Uj). We include CD4 count and use the intercept
and obstime as the random effects. The results are shown in Table 1; Obstime is
a significant predictor of CD4 cell count (t = —9.88, p-value = 0). We denote pvalue = 0 as p < 0.0001. The parameter for obstime is —0.1501, this describes the
negative effect of obstime time on CD4 cell count. For every one month increase in
observation time, the CD4 cell count decreases by 0.1501 cells per cubic millimeter of
blood. A decrease of CD4 cell counts is harmful to a patient’s autoimmune response
in ability to fight diseases. This is evidence of death or disease progression occurring
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throughout the study period.

V ij — P n + ( 3 n { U j ) +

(17)

+ £ ij

Table 1: Linear Mixed-Effects Model with Random Intercept and Slope
logLik
BIC
LME Model
AIC
7172.76 -3564.641
Random Int. and Sip. 7141.282
Random Effect
Intercept
obstime
Residuals

Intercept
obstime

StdDev
4.5065
0.1729
1.7508

Corr
(Intr)
-0.152

Estimate
7.1890
-0.1501

Std. Error
0.2222
0.0152

DF
937
937

T-Value
32.36
-9.88

P-value
0
0

In addition, we examined the treatment effect on CD4 cell count by controlling
other covariates in the model. This model (model 3) is a linear mixed-effects model
with a random intercept and random slope for obstime and the inclusion of all the
four covariates drug, gender, prevOI, and AZT. The output displayed in Table 3
shows that prevOI and obstme are significant predictors of the change in CD4 cell
counts. In comparison to Models 1 and 2, the AIC value is smaller in the model
with the added covariates (A IC = 7020.004) than the lme model with only a random
intercept (A I C = 7176.633) and the lme model with a random intercept and slope
(A IC = 7141.282). The estimate for prevOIAIDS is negative; this indicates that the
CD4 cell count decreases more for the patients with a previous diagnosis of AIDS than
the patients with no previous diagnosis of AIDS at the study entry. In agreement
to our previous models, the variable obsime is significant (p — value = 0) and has
a negative estimate. We conclude, as the observation time increases by month, the
CD4 cell count decreases by 0.1524. The estimate for the obstime is similar to the
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previous model outputs. In addition, the treatment term was found to be insignificant
and reported an estimate of 0.4544. The CD4 cell count was higher in the ddl group
than in the ddC group by 0.4544 cells. Males had lower CD4 cell counts than women
by 0.3154. Patients who experience a disease progression despite AZT therapy had
lower CD4 cell counts than patients who were intolerant to AZT by 0.2570.
Table 2: Linear Mixed-Effects Model with Random Intercept and Slope with Covari
ates_________________________________________________________________
logLik
BIC
Full LME Model
AIC
7020.004 7072.439 -3500.002
with covariates
Corr
StdDev
Random Effect
(Intr)
Intercept
4.0029
-0.18
obstime
0.1726
Residuals
1.7496
DF T-Value P-value
Estimate Std. Error
15.08 0 .0000
937
10.3869
0.6886
Intercept
0.0000
0.1514
937
-10.0686
-0.1524
obstime
0.2328
462
1.19
0.4544
0.3803
drugddl
0.6291
462
-0.48
-0.3154
0.6527
gendermale
0.0000
462
-9.66
0.4787
-4.62561
prevOIAIDS
-0.54
462
0.5868
0.4725
AZTfailure
-0.2570

Next, we extend model 3 by including an interaction effect between drug and
obstime.

Model 4 is shown in equation (18). The output in Table 3 report the

A I C = 7026.648, this value differs by 6.644. Although the interaction effect is not
significant, we keep it in the model in case the investigator is interested in it. We
then would consider Model 4 with in the interaction term in our construction of the
joint model. The interaction between drug and obstime did not have a significant
effect on the CD4 cell count. PrevOIAIDS and obstime were once again significant
predictors on CD4 cell counts. Each estimate is similar to the output from model 3
and our conclusion remain the same. We conclude, as the observation time increases
by month, the CD4 cell count decreases by 0.1628. The CD4 cell count was higher
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previous model outputs. In addition, the treatment term was found to be insignificant
and reported an estimate of 0.4544. The CD4 cell count was higher in the ddl group
than in the ddC group by 0.4544 cells. Males had lower CD4 cell counts than women
by 0.3154. Patients who experience a disease progression despite AZT therapy had
lower CD4 cell counts than patients who were intolerant to AZT by 0.2570.
Table 2: Linear Mixed-Effects Model with Random Intercept and Slope with Covari
ates____________________________________________________________ ____
logLik
BIC
Full LME Model
AIC
7020.004 7072.439 -3500.002
with covariates
StdDev
Corr
Random Effect
(Intr)
4.0029
Intercept
0.1726
-0.18
obstime
Residuals
1.7496
DF T-Value P-value
Estimate Std. Error
15.08 0 .0000
937
10.3869
0.6886
Intercept
0.0000
0.1514
937 -10.0686
-0.1524
obstime
462
1.19
0.2328
0.4544
0.3803
drugddl
0.6291
462
-0.48
-0.3154
0.6527
gendermale
0.0000
462
-9.66
0.4787
prevOIAIDS
-4.62561
-0.54
0.5868
462
-0.2570
0.4725
AZTfailure

Next, we extend model 3 by including an interaction effect between drug and
obstime.

Model 4 is shown in equation (18).

The output in Table 3 report the

A I C = 7026.648, this value differs by 6.644. Although the interaction effect is not
significant, we keep it in the model in case the investigator is interested in it. We
then would consider Model 4 with in the interaction term in our construction of the
joint model. The interaction between drug and obstime did not have a significant
effect on the CD4 cell count. PrevOIAIDS and obstime were once again significant
predictors on CD4 cell counts. Each estimate is similar to the output from model 3
and our conclusion remain the same. We conclude, as the observation time increases
by month, the CD4 cell count decreases by 0.1628. The CD4 cell count was higher
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in the ddl group than in the ddC group by 0.3841 cells. Males had lower CD4 cell
counts than women by 0.3180. The CD4 cell count decreases more for the patients
with a previous diagnosis of AIDS than the patients with no previous diagnosis of
AIDS at the study entry by 4.6281. Patients who experience a disease progression
despite AZT therapy had lower CD4 cell counts than patients who were intolerant
to AZT by 0.2538. As the observation time increases by month for the patients the
CD4 cell counts are higher for the patients in the ddl group than the ddC group by
0.0217. Both outputs suggest that male patients in the ddl group, with a previous
diagnosis of aids, and experienced a failure with AZT had worse survival outcomes.

Vij = P n -\-P i2 (ti j )+ ^ i3(tij ) x D r u g i + ^ u G e n d e ri +f3i5P r e v O I i+ ( 3 i6A Z T i + W ij (tij )+ £ij

(18)
Table 3: Linear Mixed-Effects Model with Random Intercept and Slope with Inter
action Effect
logLik
BIC
Full LME Model
AIC
with Interaction
7026.648 7084.319 -3502.324
Corr
StdDev
Random Effect
(Intr)
Intercept
4.0036
0.1734
-0.181
obstime
Residuals
1.7488
DF T-Value P-value
Estimate Std. Error
0.0000
15.09
0.6906
936
10.4243
Intercept
0.0000
-7.75
936
0.0210
obstime
-0.1628
462
0.3287
0.98
0.3841
0.3928
drugddl
0.4750
0.7146
936
0.0303
drugddLobstime
0.0217
0.6263
462
-0.49
0.6527
gendermale
-0.3180
0.0000
462
-9.67
0.4787
-4.6281
prevOIAIDS
-0.54
0.5915
462
0.4726
-0.2538
AZTfailure
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3.4

Survival D ata A nalysis

3.4.1

Sum m ary Statistics

Next, we constructed a table of the number of patients at risk for each treatment at
each observed time point (0, 2, 6, 12, 18 months) in Table 4. The number of patients
at risk for the five time points are (230, 182, 153, 102, 20) for the ddl group and (237,
186, 157, 123, 14) for ddC group. The table demonstrates that the number of people
at risk decreases at each time point for both treatments. The table also shows there
is increasing missing rate due to death, dropouts, or missed visits.
In the beginning months (0-6), the number of patients at risk for ddl was less than
the number of people at risk for ddC. We do note a strange occurrence at month 12
where the number of patients at risk for ddl decreases drastically and at 18 months
the number of patients remaining in the ddl group is greater than the number of
patients remaining in the ddC group. However, we need to consider these values
proportional to the amount of patients at baseline in each group. Thus, converting
the numbers of patients at risk, proportional to the amount of patients in each group
we obtain (1, 0.79, 0.67, 0.44, 0.09) for ddl and (1, 0.78, 0.66, 0.52, 0.06) for ddC.
Proportionally, for all time points except month 12, more people were at risk in the
ddl group compared to the ddC group. At the end of the study, there were 20 patients
remaining in the ddl group and 14 remaining in the ddC. This suggests that ddl may
be better than ddC however, we note that there was not a big difference in the number
of remaining patients between both groups.
Table 4: Number of patients at risk at months 0, 2,6,12, and 18 months
Time(Months)
12 18
2
6
0
No. At Risk
Didanosine(ddl) 230 182 153 103 20
Zalcitabine(ddC) 237 186 157 123 14
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3.4.2

K aplan-M eier Survival Curve

To further investigate the efficacy of the two treatments, we looked at the KaplanMeier estimates in Figure 3. The survival rates are plotted against the observation
times and separated by treatment group. The plot displays the survival curve for
ddC in blue and the survival rates for ddl in red. In accordance with the life table in
Table 4, in the beginning months (0-6) we see similar survival curves for ddC and ddl.
During months 6-18, the survival rates for patients in the ddC group is higher than
the survival rates for the patients in ddl. Therefore, we suspect ddC was as effective
as ddl in delaying disease progression and death. The patients assigned to ddC had
a slightly better chance of surviving than patients assigned to ddl before 18 months.
After 18 months we see the survival rate for patients assigned to ddC become worse
than the survival rate for patients assigned to ddl. It is important to note that we
have not found sufficient evidence to suggest that there is a difference in treatment
effects. To investigate the treatments further, we constructed a Cox regression model
to compare the ddl and ddC treatments while controlling other covariates in the
model such as gender, prevOI, and AZT.
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Kaplan-Meier Curve by Treatment

Figure 3: Kaplan-Meier survival curves for ddC (zalcitabine) and ddl (didanosine)
from 0-24 mont.lis.

3.4.3

C ox-Proportional Hazard M odel

In this section, we fit a cox-proportional hazard model to investigate the survival
time on the drug term and other covariates gender, prevOI, and AZT. The event is
defined as death. Using a significance level of 0.05, PrevOI is a significant predictor
of hazard. We use the exponential of the estimates shown in column 2 in Table 5

to summarize our results. The expected hazard is 1.2423 times for the patients that
were assigned ddl as compared to the patients assigned to ddC, while holding all other
covariates constant. This indicates that the ddl group had worse survival than the
ddC group, however this is not statistically significant. The male’s expected hazard is
0.7104 times of females. The expected hazard is 3.6402 times for the patients with a
previous opportunistic infection of AIDS diagnosis as compared to the patients with
no previous diagnosis of AIDS. The expected hazard for patients with AZT failure is
1.1704 times of the patients that were intolerant to AZT. This suggests that the risk
of death is greater in female patients who took drug ddl, had a previous diagnosis of
AIDS at the beginning of the study and were failure to the drug AZT.
The covariates in the model are not time-varying therefore, the regression equation
for the cox-proportional hazard model is given in equation (19).

log(Ai) = ß2i + ß22Drugi + ß23Gender i + ß24PrevOIi + ß23A Z T {

Table 5: Expected Hazard on Parameter Effects
CoxPH Model
AIC
2113.514
Z P-value
Estimate Exp(est) SE(est)
0.1464 1.482
0.138
drugddl
0.2170
1.2423
0.164
0.7104
0.2455 -1.393
gendermale
-0.3419
3.6402
0.2270 5.692 <0.0001
1.2920
prevOI
0.1634 0.964
0.335
1.1705
AZTfailure
0.1575
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Lower L
0.9324
0.4391
2.3330
0.8497

(19)

Upper L
1.655
1.149
5.680
1.612

3.5

Joint M odel

In the joint modeling, we combine the linear mixed-effects submodel (18) and coxproportional hazard submodel (19)

log(Aj) =

fa i

+ /d22 Drugi + faG enderi + /324PrevO I, + fc^AZTi + W2i{t)

(20)

The association is between Wu and W2i, which linked the two processes together
through the joint model.
In the longitudinal process, prevOI (p-value <0.0001, with 95% CI(-5.6315, 3.7498)) and observation time (p-value <0.0001, with 95% Cl (-0.2239, -0.1398)) are
still significant predictors of CD4 cell count at a 0.05 significance level. In accor
dance to the longitudinal results previously mentioned, for every one month increase
in the observation time, the CD4 cell count decreases by 0.1819. The patients with
a previous diagnosis of AIDS showed a decrease in CD4 cell count by 4.6906 com
pared to the patients without a previous diagnosis of AIDS. In the event process
the treatment factor (p-value=0.0285, with 95% Cl (1.0363,1.9044)), previous IO (pvalue=0.0098 and 95% Cl (1.1616,2.9791)), and the association component (p-value
<0.0001, with 95% Cl (0.7284,0.8407)) were significant predictors. The relative haz
ard is exp(0.3399) = 1.40 for patients assigned to drug ddl as compared to 1.28 in the
separate survival model. The relative hazard is exp(0.6207)=1.86 for the patients with
a previous diagnosis of AIDS as compared to 2.19 in the separate survival model. The
association term is the parameter that measures how strongly associated the CD4 cell
count at any particular time point t is to the risk of death of disease progression. The
association term (p-value <0.0001) is significant; the CD4 cell count was correlated
to the risk of death or disease progression. The joint model parameter estimates are
similar to the separate longitudinal and survival parameter estimates.
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Table 6: Joint Model of Longitudinal and Time-to-Event
logLik
BIC
AIC
Joint Model
8546.979 8621.613 -4255.489
Longitudinal Process
Z-value P-value Lower L Upper L
Estimate Std. Error
11.7719
9.0626
0.6912
15.0721 <0.0001
Intercept
10.4173
1.1574
-0.3755
0.3175
0.9997
0.3911
drugddl
0.3909
1.0296
0.7004
-1.5326
-0.3847
0.6536
gendermale
-0.2515
-3.7498
-5.6315
-9.7719 <0.0001
0.4800
-4.6906
prevOI
0.6507
-1.2065
-0.5865
0.5575
-0.2779
0.4738
AZTfailure
-0.1398
-0.2239
0.0214
-8.4790 <0.0001
-0.1819
obstime
-0.0492
0.0698
0.7349
0.0304
0.3386
drugddLobstime
0.0103
Event Process
Z-value P-value Lower L Upper L
Estimate Std. Error
0.0722
0.0125
-7.8441 <0.0001
-3.5044
0.4468
Intercept
1.9044
1.0363
0.0285
0.1552
2.1899
drugddl
0.3399
1.1390
0.4153
-1.4542
0.1459
-0.3742
0.2573
gendermale
2.9791
1.1616
2.5834
0.0098
0.2403
0.6207
prevIOAIDS
1.5234
0.7865
0.5920
0.5360
0.0904
0.1687
AZTfailure
0.7284
0.8407
-6.7038 <0.0001
-0.2452
0.0366
Assoct

4

M o d el S electio n and A ccu ra cy

For model comparison we examine the AIC criterion of the joint model to see if it
is smaller than the combination of the AIC criterion from the separate models. The
joint model has an AIC of 8546.979 and the separate models together have an AIC=
9140.162 (7026.648 4- 2113.514). The joint model does in fact do better than the
separate approaches because the AIC criterion for the joint model is smaller than the
AIC criterion for the separate models.

4.1

D iagnostics

We conducted model diagnostics to assess the validity of the joint model. We can
check if a model works well for data in many different ways such as residual plots,
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R 2 or AIC criterion that tell us how well a model fits the given data.

We also

assess the validity in exploration of the model’s underlying statistical assumptions,
an examination of the structure of the model by considering formulations that have
fewer, more, or different explanatory variables, or looking for influential points that
does not fit well represented by the model (outliers) or that have a relatively large
effect on the model’s predictions.

Figure 4 showed a plot of the subject-specific

residuals against the fitted values and a normal Q-Q plot of the standardize residuals
and theoretical quantiles. We performed a Shapiro Wilk test of normality and plotted
the marginal residuals against the fitted values to examine the validity of the Joint
model. We also plotted the marginal survival curve and the marginal cumulative
hazard rates against time.
The residuals vs fitted in top left corner in Figure 4 is a subject-specific residual
plot. From this plot, we can see the residual vs fitted plot shows a constraint. In the
left lower corner the residuals have a 45 degree downward slope, therefore the residuals
are not random. The Normal Q-Q plot on the top right corner in Figure 4 is also a
subject-level Q-Q plot. The Q-Q plot shows most of the residuals follow a straight
line pattern but seems to have some extreme values deviated from the straight line
pattern. W ith careful examination of the tail residuals shows strong evidence against
Normality. These are not just extreme values as we may have thought. The pattern
is consistent with a heavy-tailed distribution (such as a t-distribution).
The Shapiro-Wilk test of normality was used to determine if the residuals of the
longitudinal process in the joint model meet the normality assumption. The test
produced a test statistic W=0.9478 (p-value<0.0001), indicating the residuals are
not from a normally distributed population. However, since the test is biased by
sample size, the test may be statistically significant from a normal distribution in any
large samples. Thus, we use the Q-Q plot in the top right corner for verification in
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addition to the test.
From the marginal residual plot in Figure 5, we can see for small fitted values we
have more positive than negative residuals. Small fitted values correspond to lower
levels of square root CD4 cell count, which corresponds to a worsening of the patient’s
condition and subject to higher chance of dropout. Thus, the residuals corresponding
to small fitted values are only based on patients with a ‘good’ health condition.
The problem in the residual plot and Q-Q plot is that the distribution of the resid
uals for the longitudinal process is affected by the dropout caused by the occurrence
of events. When a patient experiences the event, it corresponds to a discontinuation
of the collection of longitudinal information because either follow up measurements
can no longer be collected or their distribution changes after the event occurred. The
dropout mechanism implied by joint models is of a nonrandom nature, which im
plies the observed data, upon which the residuals are calculated, do not constitute a
random sample of the target population [24]. This implies the residuals plots based
on the observed data alone can be misleading because these residuals should not be
expected to exhibit standard properties, such as zero mean and independence.
Even if we think there is a problem with the normality assumption, the inference
is still valid because the joint model is a more robust procedure than the classical
separate longitudinal and survival analysis and the sample size is large for this data.
You can see that the model is robust because the Q-Q plot demonstrated heavy tailed
distribution of residuals such as the t-distribution. A robust joint model still provides
accurate inference on the study objectives despite having its assumptions altered or
violated. A robust joint model works better than the separate models when a greater
proportion of more extreme longitudinal outliers are present. Through t-distribution
assumptions, longitudinal outliers are accommodated with their detrimental impact
being down weighed and thus providing more efficient and reliable estimate.
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Furthermore, the Marginal Survival curves shows a decreasing trend; as time
increases the survival rate decreases. Lastly, examining the Marginal Cumulative
Hazard curve, there is an increasing trend over time. As time increases the cumulative
hazard rate increases exponentially. Both plots indicate that the disease progressed
for the patients in the study.
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D iscu ssio n and C on clu sion

To summarize, previous authors have used separate analyses of longitudinal and timeto-event data. Common issues in longitudinal studies is that the data suffers from
attrition, which can cause bias in the analysis if the dropout are informative. Also
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associations between longitudinal and survival data can occur in the explanatory vari
ables or through stochastic dependence between the subject-specific random effects
component of the longitudinal model and of the survival model. We used a joint
model to account for these issues and simultaneously analyze the longitudinal and
time-to-event data. Our approach is important in many bio-statistical application
areas, because we obtain accurate inference regarding longitudinal responses while
A

adjusting for outcome-dependent study dropout. We can also apply these ideas to
problems involving surrogate markers, where the focus is on using longitudinal mea
surements to improve prediction of survival prognosis.
We used the HIV study to investigate the efficacy and safety of the two drugs,
Didanosine (ddl) and Zalcitabine (ddC), and how the CD4 cell counts changed over
time. In the analysis of the HIV data, we compared separate analyses of the longi
tudinal model and survival model to the joint model. The separate analysis of the
LME model with a random intercept and slope of obstime with all four covariates
showed that observation time (p-value=0) had a significant negative effect on CD4 cell
counts, indicating that for every one month increase for the observed time, the CD4
cell count decreased. PrevOIAIDS (p-value=0) had a significant negative effect on
CD4 cell count, indicating that CD4 cell counts decrease for patients with a previous
diagnosis of AIDS compared to patients with no previous diagnosis of AIDS at the
study entry. The separate cox-proportional hazard model was used to investigate the
effect the drug groups and additional covariates on the hazard. The cox-proportional
hazard model showed prevOIAIDS was significant at the 0.05 significance level. We
note that the drug term was not significant at 0.05 significance level but significant at
0.10 significance level. The expected hazard was 2.1886 times higher for patients who
were diagnosed with AIDS compared to patients who didn’t have a previous diagnosis
of AIDS at baseline.
43

The joint model showed that prevOIAIDS and obstime were significant predictors
of the change in CD4 cell count at a 0.05 significance level. Having a previous diagnosis
of AIDS as time went on in the study led to a decrease in CD4 cell counts which means
a patient was more likely to die or the disease progressed. The risk of death for
patients assigned to ddl was 1.44 times as likely compared to the patients assigned to
ddC with a significant p-value at 0.05 significance level. The association term between
the CD4 count and the survival process (p-value <0.0001) is significant; the CD4 cell
count was correlated to the risk of death. The joint model parameter estimates are
similar to the separate longitudinal and survival parameter estimates. It also showed
the two drug groups had significant hazard rate when controlling other covariates in
the joint model. Model diagnostic showed the joint model fit the data well. W ith the
model diagnostic results and a significant association between the longitudinal process
and survival process, the joint model approach provides valid and accurate results for
the HIV study. The joint model can be readily fit using the jointModel function under
the JM package in R, thus avoiding the need for complex EM programming. This
makes it more convenient to use in real data analysis.
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